In a regulatory filing, BioXcel Therapeutics (BTAI) announced that the United States Patent and Trademark Office had allowed U.S. Patent Application No. 18/600,419 with claims pertaining to the administration of a single dose of up to 120 mcg of dexmedetomidine in an oromucosal formulation for the treatment of acute agitation associated with schizophrenia or bipolar disorder in certain patient subpopulations where the patient exhibits a maximum allowed QT prolongation of less than six microseconds. The allowed claims mirror the recommended IGALMI dosing regime for treatment of patients meeting this QT prolongation criteria. Once issued, this patent will be eligible for listing in the Orange Book for Igalmi and will be the 14th Orange Book listed patent for Igalmi. This patent will have an expiry date of January 12, 2043, subject to patent term adjustment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Granted Patent for Dexmedetomidine Use
- Positive Buy Rating for Bioxcel Therapeutics Driven by Promising Phase 3 Trial Developments and Valuation Alignment
- BioXcel Therapeutics reports DSMB recommends continuation of SERENITY trial
- BioXcel Therapeutics initiated with a Buy at Lucid Capital
- BioXcel Therapeutics target adjusted to $8 from $3 at H.C. Wainwright